Novo Nordisk A/S engages in the research, development, manufacture, and distribution of pharmaceutical products, primarily focusing on diabetes and obesity care, as well as rare diseases. Its main revenue segments include Diabetes and Obesity Care (approximately 80% of revenue) and Rare Disease (approximately 20% of revenue). The company offers a range of products including insulin pens, growth hormone pens, and smart diabetes management solutions. Factors supporting its endurance include a strong portfolio of diabetes treatments and a growing global prevalence of obesity, while potential limitations include regulatory challenges and competition from generic drug manufacturers.
—
Novo Nordisk A/S engages in the research, development, manufacture, and distribution of pharmaceutical products, primarily focusing on diabetes and obesity care, as well as rare diseases. Its main revenue segments include Diabetes and Obesity Care (approximately 80% of revenue) and Rare Disease (approximately 20% of revenue). The company offers a range of products including insulin pens, growth hormone pens, and smart diabetes management solutions. Factors supporting its endurance include a strong portfolio of diabetes treatments and a growing global prevalence of obesity, while potential limitations include regulatory challenges and competition from generic drug manufacturers.
—
Daily adjusted close
Novo Nordisk A/S engages in the research, development, manufacture, and distribution of pharmaceutical products, primarily focusing on diabetes and obesity care, as well as rare diseases. Its main revenue segments include Diabetes and Obesity Care (approximately 80% of revenue) and Rare Disease (approximately 20% of revenue). The company offers a range of products including insulin pens, growth hormone pens, and smart diabetes management solutions. Factors supporting its endurance include a strong portfolio of diabetes treatments and a growing global prevalence of obesity, while potential limitations include regulatory challenges and competition from generic drug manufacturers.